UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Inflammatory bowel diseases, 2012-01, Vol.18 (1), p.1-9

2012

Volltextzugriff (PDF)

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

Journal of Crohn's & colitis, 2010-02, Vol.4 (1), p.7-27

2010

Volltextzugriff (PDF)

Stopping Biologics in IBD-What Is the Evidence?

Inflammatory bowel diseases, 2018-03, Vol.24 (4), p.725-731

Louis, Edouard

2018

Volltextzugriff (PDF)

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects

Journal of Crohn's and colitis, 2010-10, Vol.4 (4), p.355-366

2010

Volltextzugriff (PDF)

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Inflammatory bowel diseases, 2007-02, Vol.13 (2), p.135-142

2007

Volltextzugriff (PDF)

Interobserver Variation Study of the Rutgeerts Score to Assess Endoscopic Recurrence after Surgery for Crohn’s Disease

Journal of Crohn's and colitis, 2016-09, Vol.10 (9), p.1001-1005

2016

Volltextzugriff (PDF)

Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience

Journal of Crohn's and colitis, 2016-05, Vol.10 (5), p.516-524

2016

Volltextzugriff (PDF)

Do We Still Need Predictors of Disease Severity When Applying a Treat-to-Target Approach in Inflammatory Bowel Disease?

Journal of Crohn's and colitis, 2019-03, Vol.13 (4), p.399-400

Louis, Edouard

2019

Volltextzugriff (PDF)

Monomeric Calgranulins Measured by SELDI-TOF Mass Spectrometry and Calprotectin Measured by ELISA as Biomarkers in Arthritis

Clinical chemistry (Baltimore, Md.), 2008-06, Vol.54 (6), p.1066-1075

2008

Volltextzugriff (PDF)

Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice

Journal of Crohn's and colitis, 2015-01, Vol.9 (1), p.1-3

Louis, Edouard

2015

Volltextzugriff (PDF)

The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease

Journal of Crohn's and colitis, 2019-09, Vol.13 (10), p.1323-1333

2019

Volltextzugriff (PDF)

Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?

Journal of Crohn's and colitis, 2021-07, Vol.15 (7), p.1087-1088

2021

Volltextzugriff (PDF)

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

Inflammatory bowel diseases, 2011-03, Vol.17 (3), p.858-859

Louis, Edouard

2011

Volltextzugriff (PDF)

Clinical and MRI Evolution After Local Injection of Bone Marrow-Derived Mesenchymal Stem Cells in Perianal Fistulae in Crohn’s Disease: Results From a Prospective Monocentric Study

Journal of Crohn's and colitis, 2023-05, Vol.17 (5), p.728-737

2023

Volltextzugriff (PDF)

European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2018-01, Vol.12 (1), p.17-31

2018

Volltextzugriff (PDF)

Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study]

Journal of Crohn's and colitis, 2023-03, Vol.17 (2), p.231-239

2023

Volltextzugriff (PDF)

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Inflammatory bowel diseases, 2019-01, Vol.25 (1), p.156-162

2019

Volltextzugriff (PDF)

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

Inflammatory bowel diseases, 2014-06, Vol.20 (6), p.978-986

2014

Volltextzugriff (PDF)

Defining Biological Remission in Crohn’s Disease: Interest, Challenges and Future Directions

Journal of Crohn's and colitis, 2023-11, Vol.17 (10), p.1698-1702

2023

Volltextzugriff (PDF)

Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn’s Disease

Inflammatory bowel diseases, 2024-09

2024

Volltextzugriff (PDF)

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Inflammatory bowel diseases, 2024-02, Vol.30 (2), p.240-246

2024

Volltextzugriff (PDF)

Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn’s Disease

Journal of Crohn's and colitis, 2022-06, Vol.16 (5), p.693-694

2022

Volltextzugriff (PDF)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2017-03, Vol.23 (3), p.333-340

2017

Volltextzugriff (PDF)

Mesenchymal Stem Cell Injection in Crohn’s Disease Strictures: A Phase I–II Clinical Study

Journal of Crohn's and colitis, 2022-03, Vol.16 (3), p.506-510

2022

Volltextzugriff (PDF)

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study

Journal of Crohn's and colitis, 2019-10, Vol.13 (11), p.1401-1409

2019

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals 2020 Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(132)

Publikationsform

Sprache

Englisch
(133)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

Stopping Biologics in IBD-What Is the Evidence?

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Interobserver Variation Study of the Rutgeerts Score to Assess Endoscopic Recurrence after Surgery for Crohn’s Disease

Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience

Do We Still Need Predictors of Disease Severity When Applying a Treat-to-Target Approach in Inflammatory Bowel Disease?

Monomeric Calgranulins Measured by SELDI-TOF Mass Spectrometry and Calprotectin Measured by ELISA as Biomarkers in Arthritis

Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice

The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease

Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

Clinical and MRI Evolution After Local Injection of Bone Marrow-Derived Mesenchymal Stem Cells in Perianal Fistulae in Crohn’s Disease: Results From a Prospective Monocentric Study

European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease

Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study]

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

Defining Biological Remission in Crohn’s Disease: Interest, Challenges and Future Directions

Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn’s Disease

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn’s Disease

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Mesenchymal Stem Cell Injection in Crohn’s Disease Strictures: A Phase I–II Clinical Study

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study

Aktive Filter

Suchergebnisse filtern